biosimilar

CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that they have entered into an agreement whereby Samsung Biologics will acquire Biogen’s…

Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit growth in the next several quarters, primarily from…

On October 18, 2021, MedPage Today reported on the approval of Cyltezo, the first…

The approval of biosimilars in the U.S. is lagging behind that of European countries, a pharmacist said during the American Society…

DRL gets rights to commercialise proposed trastuzumab biosimilar in select LatAm, S-E Asia markets. Pharma major Dr. Reddy’s Laboratories has entered into a partnership with Prestige…

Five-year follow-up results reconfirm comparable long-term efficacy of SB3 (ONTRUZANT®, trastuzumab-dttb) versus Herceptin® through additional analysis with a larger group of patients with…

Interchangeable biosimilars SEMGLEEA (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high…

The FDA approved Cyltezo as the first interchangeable biosimilar to adalimumab (Humira), with…

Pune, India, Oct. 06, 2021 (GLOBE NEWSWIRE) -- This information is provided by Fortune Business Insights™ in a recent report, the report further mentions that the Active Pharmaceutical…

Welcome to the latest edition of Investigative Roundup, highlighting some of the best…